Gains by Kinobody — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
50% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

5 Vegetarian Capsule(s) Serving Size

30 Servings

Non-Nutrient/Non-Botanical Product Type

50% Evidence Coverage

Supplement Facts — Evidence Check

Creatine Hydrochloride

2000 mg

📊 Market median: 5.0mg (298 products) 📚 701 studies (Tier A: 5, B: 123)

This product: 2000mg

Betaine Hydrochloride

1500 mg

📊 Market median: 496.0mg (192 products) 📚 20 studies — no high-quality reviews

This product: 1500mg

Other Ingredients

Microcrystalline Cellulose Hydroxypropyl Methylcellulose Magnesium Stearate Silicon Dioxide

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (98% of products) Structure/Function (93% of products) Nutrient (20% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Gains has 30 servings per container. Take 5 capsules daily with food and 10 oz of water

🧪 Formulation Notes

Kino Gains is designed to support maximum muscle growth while maintaining clear definition with two key supplements.

Creatine hydrochloride - powers strength and muscle growth without blurring definition like conventional creatine. Betaine - works synergistically to hydrate your muscles and increase protein synthesis for greater muscle growth.

Creatine HCl and Betaine

Supports strength and power, muscle recovery and muscle growth Highly bio-available Natural ingredients No bloating Signature series formula

GMO free product Soy free Dairy free Gluten free

Additional Information

cGMP Registered Facility 30 Days Money Back

Product Details

UPC / SKU 1 98168 90038 3

DSLD Entry Date 2025-08-22

Product Type Non-Nutrient/Non-Botanical

Form Capsule

Brand Kinobody

DSLD ID 339063

Data Updated 2026-04-11

Research Evidence

739 Research Sources

47 Avg Quality Score

472 Clinical Trial

139 Meta Analysis

74 Systematic Review

47 Rct

2 Regulatory Source

1 Cochrane Review

1 Guideline

1 Openfda Safety

A Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data

Meta Analysis JAMA psychiatry 2021

PubMed DOI

A HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

B Greater Choline-Containing Compounds and Myo-inositol in Treatment-Resistant Versus Responsive Schizophrenia: A 1H-Magnetic Resonance Spectroscopy Meta-analysis

Meta Analysis Biological psychiatry. Cognitive neuroscience and neuroimaging 2024

PubMed DOI

B Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis

Systematic Review BMC medicine 2019

PubMed DOI

B Efficacy of Creatine Supplementation Combined with Resistance Training on Muscle Strength and Muscle Mass in Older Females: A Systematic Review and Meta-Analysis

Meta Analysis Nutrients 2021

PubMed DOI

B The Effects of Creatine Supplementation on Upper- and Lower-Body Strength and Power: A Systematic Review and Meta-Analysis

Meta Analysis Nutrients 2025

PubMed DOI

B Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease

Meta Analysis Medicine 2026

PubMed DOI

B Creatine and creatine analogues in hypertension and cardiovascular disease

Meta Analysis The Cochrane database of systematic reviews 2011

PubMed DOI

B HMG CoA reductase inhibitors (statins) for dialysis patients